PANVAC - VF Synopsis (PDF)

PROSTVAC^® - VF Synopsis (PDF)

	Home > Clinical Studies

Therion's cancer immunotherapy platform reflects over 10 years of clinical experience involving over 30 clinical trials in more than 700 patients, chiefly through the company's longstanding partnership with the NCI (National Cancer Institute). These extensive clinical trials of multiple vaccine components and prototypes have enabled Therion to optimize its technology platform and maximize the probability for downstream success. Therion's two lead product candidates, PANVAC-VF for pancreatic cancer and PROSTVAC^®-VF for prostate cancer, are the direct result of these efforts. Previous clinical studies suggested disease stabilization, delayed time to progression, tumor-specific immune responses, and that the vaccine candidate was well tolerated. Therion has presented its clinical results in several peer-reviewed publications and presentations, many of which can be accessed in the Press Room section of this website.

Ongoing and planned clinical studies include:
PANVAC-VF - Entering a Phase III study in refractory pancreatic cancer
PROSTVAC^®-VF - Phase II study in metastatic, androgen-independent prostate cancer

Therion is also working closely with the National Cancer Institute, Aventis Pasteur, and a network of leading clinical institutions to develop treatments for other major indications, including bladder cancer, breast cancer, colorectal cancer, and lung cancer, as well as a preventative AIDS vaccine.

The pipeline chart below illustrates the status of studies being conducted by Therion and in collaboration with its partners, as noted: